http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109078198-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4df209b7f4f2ab9a3960cd1caa5f4593 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1027 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K101-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate | 2018-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe390e467cfccd4b11e0f7ea73e4344c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_587a99eedb8ce259a5d4303b2c6037cc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e2106a13b74a01b0a6ad8f7b8b0c0ff |
| publicationDate | 2018-12-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109078198-A |
| titleOfInvention | Application of a molecular probe 131I-ch4E5 targeting B-cell lymphoma |
| abstract | The present invention relates to the application of a molecular probe 131 I-ch4E5 targeting B-cell lymphoma. The present invention includes the following experimental steps: preparation of the molecular probe 131 I-ch4E5, activity determination of 131 I-ch4E5, and 131 I-ch4E5 The following characteristic parameters were detected: labeling rate, radiochemical purity, cell binding rate of 131 I-ch4E5, killing effect of 131 I-ch4E5 on cells, and distribution of 131 I-ch4E5 in tumor-bearing nude mice. The experimental results show that the molecular probe 131 I‑ch4E5 prepared by this method has high labeling rate and radiochemical purity, and both in vivo and in vitro experiments show that it has good targeting ability to B cell lymphoma and has strong killing effect on lymphoma cells It is expected to be used in CD80-targeted radioimmunoimaging and treatment of B-cell lymphoma. |
| priorityDate | 2018-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 42.